Department of Health and Human Services Awarded a Contract to AVANTGEN INC for $1,497,384.00

Summary of Award

The awarded contract between the U.S. federal government and Avantgen Inc., detailed in the above JSON data from usaspending.gov, underscores significant federal investments in biotechnology research. The focal point of this award is the development of rabbit monoclonal antibodies tailored specifically for ferret biomarkers. This venture signifies a strategic initiative spearheaded by the Department of Health and Human Services (HHS) through its National Institutes of Health (NIH) division, specifically the National Institute of Allergy and Infectious Diseases (NIAID).

**Contract Overview**

The contract, identified by the unique award ID "CONT_AWD_75N93025C00013_7529_-NONE-_-NONE-," is categorized as a definitive contract (Type D), indicating a traditional procurement strategy for a specified project scope. The award amount consists of total obligations amounting to $1,497,384, which highlights the government’s commitment to utilizing biotechnology for healthcare and disease prevention purposes. The primary focus of this contract is on developing rabbit monoclonal antibodies for ferret biomarkers, which provides essential insights into specific infections and diseases. This project could play a crucial role in understanding and curbing zoonotic infections, significantly impacting both animal and human health. With no subawards under this contract, the total financial obligation rests solely with Avantgen Inc., ensuring concentrated efforts from this biotechnology firm. **Funding and Awarding Agencies** Funding and oversight for this contract are managed by the HHS's NIH, a vital institution in healthcare research. The NIAID office is actively participating as both the offering and awarding agency, reflecting a streamlined approach where a single entity ensures coherence in administrative and financial control. **Contract Details and Transaction** The agreement was signed on January 14, 2025, with the performance period stretching from February 1, 2025, to January 31, 2028. This setup provides Avantgen Inc. with a three-year window to fulfill all research and development obligations mandated by the contract. One fundamental aspect of this contract is its firm-fixed-price nature. This pricing type offers predictability in budget planning for the government, ensuring that regardless of future resource costs or market changes, contract costs remain stable. The contract emerged from a highly competitive landscape, with 12 proposals received through a solicitation process described as "negotiated proposal/quote". Extending beyond competition norms, the opportunity was fully open to all capable entities, reinforcing the government's commitment to transparency and equity in federal procurements. **Recipient Details: Avantgen Inc.** Avantgen Inc., the recipient of the contract, is a U.S.-based small business operating out of San Diego, California. Identified by the UEI WLNHKNPNT2M7, the company specializes in research and development within the biotechnology sector, separate from nanobiotechnology endeavors. Positioned in the vital entrepreneurial hub of Southern California, the firm is well-situated to leverage regional scientific and technological frameworks. As a small business entity with various category designations, including "Corporate Entity Not Tax Exempt" and "U.S.-Owned Business," Avantgen Inc. exemplifies the vigorous innovation ecosystem fostered by the U.S. government's strategic support and investment. The presence of the business within the San Diego area, which typically boasts a strong scientific community and supportive infrastructure, further bolsters its capacity to meet the contract requirements. **Purpose and Strategic Importance** The project embarked upon by Avantgen has profound implications. The planned development of monoclonal antibodies aims to enhance scientific understanding and treatment of diseases that could transition between animal hosts and potentially affect human populations. Investing in such research aligns with global health priorities, echoing foresight in addressing emerging infectious threats. This contract’s structuring underscores the strategic use of federal procurement to boost scientific breakthroughs and uphold public health safety nets. The health R&D services outlined in the contract cater to an urgent and ongoing need for advanced medical research solutions, paving the way for potential innovations in disease diagnosis, treatment, and prevention. **Transaction Records and Performance Monitoring** Initial contract actions indicate a steady transition from award to activation. Detailed transaction records help in ensuring accountability and performance evaluation, acting as an assurance to all involved entities of the planned deliverables and corresponding timelines. This diligent recording of contract modifications is exhibited in transaction entries like "P00001," although with no financial transaction amount specified at this stage. The documentary transparency, accompanied by precise data-driven reporting, empowers both federal authorities and contractor entities to actively oversee project progress. Through systemic checks and balances, the potential for realigning resources or stipulations remains, granting adaptive flexibility to suit emergent challenges. **Conclusion** The collaboration between Avantgen Inc. and the NIH through this contract exemplifies the vital role government-backed research plays in advancing public health frontiers. By fostering specific avenues of biotechnology development, especially those addressing pressing healthcare challenges through monoclonal antibodies and biomarker insights, the federal government not only drives innovative exploration but also safeguards national and global health imperatives.